Development of a Predictive Model for Treatment Outcome and Treatment-related Morbidity in a Prospective Cohort Study of Patients With Lymphoma
Overview
- Phase
- Not Applicable
- Intervention
- Chemotherapy with or without radiotherapy
- Conditions
- Lymphoma
- Sponsor
- Samsung Medical Center
- Enrollment
- 953
- Locations
- 1
- Primary Endpoint
- all cause mortality
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.
Detailed Description
Although the cure rate of lymphoma has been increased due to the development of newer effective drugs, a substantial portion of patients is still suffered from relapse. Furthermore, the treatment-related morbidity is another factor which can make the treatment outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is going to assess following factors which amy probably affect the treatment outcome and the risk of treatment-related morbidity. 1. Biologic factors associated with the aggressiveness of lymphoma * molecular markers in serum, cytogenetic markers 2. Factors associated with the risk of treatment-related morbidity * comorbidity, nutrition status, performance status, quality of life at diagnosis
Investigators
Kim, Seok Jin
Associate Professor
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •Patients who were diagnosed as lymphoma
- •Over 15 years old
- •Patients who agreed the enrollment of study
- •Informed consent for sampling
Exclusion Criteria
- •Patients who do not want to join the study
Arms & Interventions
Lymphoma
patients diagnosed as lymphoma
Intervention: Chemotherapy with or without radiotherapy
Outcomes
Primary Outcomes
all cause mortality
Time Frame: 5 years
Secondary Outcomes
- Treatment response(after completion of primary therapy)
- Rate of occurrence of toxicity(2 years from the start of the 1st therapy)
- Treatment-related morbidity(within 60 days from the previous therapy)